These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 19036706)
1. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Fakler M; Loeder S; Vogler M; Schneider K; Jeremias I; Debatin KM; Fulda S Blood; 2009 Feb; 113(8):1710-22. PubMed ID: 19036706 [TBL] [Abstract][Full Text] [Related]
2. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553 [TBL] [Abstract][Full Text] [Related]
3. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Loeder S; Drensek A; Jeremias I; Debatin KM; Fulda S Int J Cancer; 2010 May; 126(9):2216-28. PubMed ID: 19676052 [TBL] [Abstract][Full Text] [Related]
4. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513 [TBL] [Abstract][Full Text] [Related]
5. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934 [TBL] [Abstract][Full Text] [Related]
6. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673 [TBL] [Abstract][Full Text] [Related]
7. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. Danish L; Imig D; Allgöwer F; Scheurich P; Pollak N PLoS One; 2018; 13(6):e0198203. PubMed ID: 29927992 [TBL] [Abstract][Full Text] [Related]
8. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200 [TBL] [Abstract][Full Text] [Related]
9. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781 [TBL] [Abstract][Full Text] [Related]
10. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Fulda S; Meyer E; Debatin KM Oncogene; 2002 Apr; 21(15):2283-94. PubMed ID: 11948412 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Gillissen B; Richter A; Richter A; Overkamp T; Essmann F; Hemmati PG; Preissner R; Belka C; Daniel PT Cell Death Dis; 2013 May; 4(5):e643. PubMed ID: 23703388 [TBL] [Abstract][Full Text] [Related]
13. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560 [TBL] [Abstract][Full Text] [Related]
14. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
15. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080 [TBL] [Abstract][Full Text] [Related]
16. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. Weng C; Li Y; Xu D; Shi Y; Tang H J Biol Chem; 2005 Mar; 280(11):10491-500. PubMed ID: 15637055 [TBL] [Abstract][Full Text] [Related]
17. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915 [TBL] [Abstract][Full Text] [Related]
18. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
19. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Rosato RR; Almenara JA; Coe S; Grant S Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059 [TBL] [Abstract][Full Text] [Related]
20. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Saraei R; Soleimani M; Movassaghpour Akbari AA; Farshdousti Hagh M; Hassanzadeh A; Solali S Biomed Pharmacother; 2018 Nov; 107():1010-1019. PubMed ID: 30257312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]